novo nordisk semaglutide nash NVO Detailed Phase 2 (GLP-1 agonist) data in #NASH. At 0.4 mg, 33/56 pts had resolution vs 10/58 pts on pbo (58.9% vs 17.2%). Notably, the trial didn't achieve a Novo Nordisk's weight-loss pill wins

While pancreatic enzymes (lipase, amylase) are not routinely monitored, they might be checked if pancreatitis is suspected based on symptoms

During committee discussions, some lawmakers raised concerns about both the cost of the drugs and the potential side effects, which they say could lead to additional medical expenses paid for by taxpayers

This treatment can help patients prone to overeating and snacking to feel fuller for longer, so theyre less likely to step out on their diet

When these symptoms do not resolve with dose adjustments or supportive measures, switching to a different mechanism becomes the most logical path forward

They track their experience for the first 4 weeks and then stop overanalyzing

However, several challenges need to be addressed to optimize their clinical utility